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Available online 24 July 2012AbstractGroup B Streptococcus (GBS) is the leading cause of neonatal septicemia and meningitis. Pili appendages were shown to play a critical role
in bacterial adhesion and colonization of human tissues. Recently it was claimed that binding of the pilus-associated adhesin PilA to collagen is
a critical, initial step in promoting interactions with the a2b1 integrin expressed on brain endothelial cells. Here we show that strain NCTC10/84
used in this study is not representative for GBS isolates and question the importance of collagen as a critical extracellular matrix component for
GBS infections of the central nervous system.
 2012 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
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Streptococcus agalactiae (also known as Group B Strep-
tococcus, GBS) is the leading cause of neonatal infections in
the industrialized world. The first systematic review and meta-
analysis of neonatal Group B Streptococcal disease shows that
five serotypes (Ia, Ib, II, III and V) are responsible for the
global burden of disease [1]. Among those, serotype III is of
major importance in neonatal diseases whereas serotype V is
mainly involved in adult invasive diseases. Several epidemi-
ological studies, including a recent report from our laboratory
[2], pinpoint a single GBS clone of capsular serotype III,
designated ST17 according to its sequence type (ST) as being
responsible for the vast majority (>80%) of meningitis cases
[3e8]. The ST17 clone is now worldwide referred to as the
hypervirulent GBS clonal complex 17 (CC-17) and COH1,* Corresponding author. Institut Pasteur, Paris, France. Tel.: þ33 (0)1 44 38
94 87; fax: þ33 (0)1 45 68 89 38.
E-mail address: shaynoor.dramsi@pasteur.fr (S. Dramsi).
1286-4579/$ - see front matter  2012 Institut Pasteur. Published by Elsevier Ma
http://dx.doi.org/10.1016/j.micinf.2012.07.004a representative strain of this group, has been sequenced
recently [9].
Surface-exposed pili has emerged as appealing host colo-
nizing factors as well as vaccine antigen candidates. We and
others have initially characterized pili in S. agalactiae
[10e12] and have demonstrated their role in adhesion to host
cells and in biofilm formation. Two genomic pilus islands (PI-
1 and PI-2) have been identified in GBS. Of note, the PI-2
locus exists in two variant forms: PI-2a (73%) being present
in the vast majority of GBS strains belonging to all serotypes
and PI-2b (27%) being restricted to ST17 and a few other
clinical isolates. The overall organization of each PI locus is
similar as it contains three genes that encode cell wall
anchored LPXTG proteins and two genes encoding class C
sortases involved in pilus assembly. The PI-2a pilus is
composed of the major backbone protein (PilB) decorated
with the tip adhesin (PilA) and attached to the bacterial cell
wall with the pilus-anchoring subunit (PilC) [10,13]. In non-
ST17 strains, lack of PilA was associated with a significant
decrease in the ability of bacteria to bind to human epithelialsson SAS. All rights reserved.
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estingly PilA contains a Von Willebrand type A factor domain
(VWA), a domain known to tightly bind to collagens present
on the vessel wall and to control platelet adhesion to the
damaged vasculature. This VWA was shown to be mandatory
for adhesive properties of PilA [14]. A recent report from
Banerjee et al. proposed that binding of the pilus-associated
adhesin PilA to collagen is a critical initial step in
promoting interactions with the a2b1 integrin expressed on
brain endothelial cells. Activation of this host receptor was
reported to cause focal adhesion kinase (FAK) activation and
downstream phosphatidylinositol-3 phosphate kinase (PI3K)
and MAPK signaling, resulting in host chemokine expression
and neutrophil recruitment during infection and bacterial entry
into the central nervous system (CNS) [16]. Banerjee et al.
have used the GBS strain NCTC10/84 which is a clinical
isolate of capsular serotype V, a serotype not normally asso-
ciated with meningitis. On the other hand, Al Safadi et al.
proposed that human fibrinogen is the extracellular matrix
(ECM) component critical for CNS infections caused by CC-
17 isolates [17]. In this brief report, we tested the binding
capacity of randomly selected clinical GBS isolates to bind to
collagen and fibrinogen. Our results question the choice of
GBS strain NCTC10/84 as a relevant representative to study
GBS-host interactions, in particular CNS invasion.
2. Material and methods2.1. Bacterial adherence to ECM componentsGBS and Streptococcus gallolyticus were grown in Todd-
Hewitt (TH) broth whereas recombinant Lactococcus lactis
was grown in M17 1% glucose containing erythromycin at
5 mg/ml. Polystyrene 96-wells plates (NUNC) were coated
with collagen I (from rat tail, BD Biosciences) or collagen IV
(from human cell culture, SigmaeAldrich C6745) at 50 mg/ml
(100 ml per well) and incubated overnight at 4 C. After
saturation of non-specific sites with Superblock Buffer
(Thermo Scientific), approx. 108 bacterial colony forming
units (cfu) were added and the plates were incubated for 2 h at
37 C. Non-adherent bacteria were removed using the ELx50
Microplate Strip Washer (BioTek). Adherent bacteria were
stained with 0.1% crystal violet for 30 min, washed twice
with PBS, and air-dried for 15 min. The stained bacteria
were resuspended for quantification in ethanol/acetone
(80:20). The plate was scanned and absorbance at 595 nm was
measured. Similar experiments were performed with human
fibrinogen purchased from SigmaeAldrich (from human
plasma F3879).2.2. Hemolysin assayApproximately 2  108 cfu of GBS cells were collected
from liquid cultures at exponential phase, washed once with
phosphate-buffered saline (PBS), and resuspended in 1 ml of
PBS containing 0.2% glucose. Serial dilutions (2-fold) of this
suspension in PBS containing 0.2% glucose were mixed withan equal volume of 1% sheep erythrocytes (RBC) in the same
buffer and incubated at 37 C for 1 h. After incubation,
unlysed RBC and bacteria were removed by centrifugation and
hemoglobin content of the supernatant was assessed by
measuring absorbance at 420 nm (A420). The hemolytic titer
of each strain was determined as the reciprocal of the greatest
dilution producing 50% hemoglobin release compared to
control samples in which all RBC were lysed by sodium
dodecyl sulfate (SDS 0.2%).
3. Results and discussion3.1. Binding of clinical GBS isolates to collagen and
fibrinogenWe investigated the ability of 20 GBS strains isolated from
invasive neonatal disease (10 non-ST17 and 10 ST17 strains
that were randomly selected) to bind to collagen type I, type
IV, and fibrinogen. We found no significant binding to
collagen I and IV as compared to the positive control S. gal-
lolyticus, a collagen-binding species causing endocarditis [18]
(Fig. 1A and data not shown). Furthermore, recombinant
strains of L. lactis overexpressing either PilA or the entire PI-
2a pilus of GBS strain NEM316 did not bind to collagen I or
IV, unlike L. lactis overexpressing the collagen-binding Pil1 of
S. gallolyticus (Fig. 1A and data not shown). These results
indicate that the PilA protein is most likely not directly
responsible for collagen binding.
In contrast, all 20 GBS strains were able to bind to human
fibrinogen at various levels in a dose-dependent manner. All
ST17 isolates displayed higher binding as compared to non-
ST17 strains (Fig. 1B). The representative assay shown in
Fig. 1B was conducted as blind test. The isolates marked by an
asterisk were predicted as being ST17 strains based on their
increased fibrinogen binding phenotype. This prediction was
later indeed confirmed to 100%. These results are in perfect
agreement with a recent study [17] suggesting that the higher
fibrinogen binding ability of CC-17 strains may participate in
their enhanced invasiveness for neonates as compared to
strains of other CCs.3.2. GBS strain NCTC10/84 is an atypical clinical
isolateThe GBS strain NCTC10/84 (also called 1169-NT1) is of
capsular serotype V and was isolated from blood of a septic
neonate [19]. Its genome has not been sequenced yet. We
determined that strain NCTC10/84 belongs to the ST-26
(http://pubmlst.org/sagalactiae/), a worldwide very rare
sequence type [20,21] although it is representing 15% of GBS
isolates from the Central African Republic and Senegal [22].
It is interesting to note that Doran et al. previously reported
that the beta-haemolysin/cytolysin (b-h/c) of GBS activates
specific signaling pathways in human brain microvascular
endothelial cells (HBMEC) resulting in IL-8 release, neutro-
phil recruitment and enhanced virulence [23]. The b-h/C toxin
was identified as the principal factor responsible for blood-
Fig. 1. A e Adherence of GBS wild type strains and Lactococcus recombinant strains to immobilized collagen I (Col I). Microtiter wells were coated with 5 mg of
Col I and 107 cfu were added. Adherent bacteria were detected using crystal violet staining. The two horizontal rows represent sample duplicates. Upper panel e 20
GBS neonatal isolates 10 of which are ST17* and 10 non-ST17 (for details see Table 1). Streptococcus gallolyticus (S. gallo strain UCN34) is used as positive
control. Lower panel e Adherence of L. lactis NZ9000/pOri23 and its various derivatives. Similar results were obtained with human collagen IV (not shown).
B e Adherence of GBS wild type strains to immobilized human fibrinogen (3 mg per well).
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COH1, and NCTC10/84. We thus compared the hemolytic
activity of the seven sequenced GBS strains (NEM316,
2603V/R, A909, COH1, H36B, 515, and 18RS21) and 20
additional GBS isolates from neonatal disease that we have
previously used [2]. Most clinical isolates belonging to
different ST groups, including ST17, were less hemolytic than
our reference strain NEM316 WT (Fig. 2, Table 1). The
hemolysin-negative mutant NEM316DcylE and the hyper-
hemolytic mutant NEM316DcovSR were used as negative and
positive controls, respectively. Strikingly, GBS NCTC10/84
appeared to be as hemolytic as the hyperhemolytic mutant
NEM316DcovSR (Fig. 2B, Table 1). In view of these two
relevant characteristics i) the epidemiological rarity and ii)Fig. 2. Hemolytic activity of sequenced GBS strains. The hemolysin-negative mut
strain NEM316 were used as negative and positive controls, respectively. A e Hemo
e GBS streaking on horse blood agar plate. The data shown here are representatia hyperhemolytic phenotype, we conclude that NCTC10/84 is
an atypical GBS strain.
In conclusion, the role of the PilA-collagen interaction in
the process of CNS invasion by GBS is questionable. We
suggest that the unusual hyperhemolytic phenotype of GBS
strain NCTC10/84 impacts on the cellular and host responses
described in the report by Banerjee et al., precluding any
definitive conclusion about the role of the pilus-associated
adhesin PilA. The many roles uncovered for GBS pili
including bacterial adherence to host cells, biofilm formation,
and virulence were attributed to the PI-2a pilus. Importantly,
the ST17 hypervirulent clone contains two other pilus loci, PI-
1 and PI-2b, whose function(s) remains unveiled. The eluci-
dation of their role is the subject of our ongoing investigations.ant DcylE and the hyperhemolytic mutant DcovSR derived from our reference
globin release in supernatants quantified by absorbance measurement (A420). B
ve of at least three independent experiments.
Table 1
Main characteristics of the clinical GBS isolates used in this study.
GBS strains Capsular serotype ST cluster Type of neonatal infection Hemolytic index (relative value) Col I or IV binding
Clinical isolates
1 II 28 EOD/bacteremia 16e32 -
2 Ia 23 EOD/meningitis 8 -
3 Ia 23 EOD/bacteremia 8 -
4 Ia 23 EOD/bacteremia 4e8 -
5 III 17 LOD/meningitis 4e8 -
6 III 17 LOD/meningitis 16e32 -
7 III 17 LOD/meningitis 8e16 -
8 Ia 24 EOD/bacteremia 8e16 -
9 III 17 EOD/bacteremia 4e8 -
10 III 17 LOD/meningitis 4 -
11 III 17 LOD/meningitis 4e8 -
12 Ia 23 EOD/bacteremia 4e8 -
13 III 17 EOD/meningitis 4e8 -
14 III 17 LOD/meningitis 4e8 -
15 V 453 EOD/bacteremia 4e8 -
16 V 1 LOD/bacteremia 4e8 -
17 III 17 EOD/meningitis 4e8 -
18 Ib 10 EOD/meningitis 4e8 -
19 Ia 23 LOD/bacteremia 4e8 -
20 III 17 LOD/meningitis 4e8 -
Reference strains
2603V/R V 110 ND 32 -
A909 Ia 7 ND 8e16 -
COH1 III 17 ND 8e16 -
18RS21 II 19 ND 4e8 -
H36B Ib 6 ND 4e8 -
515 Ia 23 ND 32e64 -
NEM316 III 23 ND 32e64 -
NEM316DcovSR III 23 ND >128 -
NEM316DcylE III 23 ND 4e8 -
NCTC10/84 V 26 Septicemia >128 -
ND: not determined; (-): negative result.
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